A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)
NCT ID: NCT00148486
Last Updated: 2013-10-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
261 participants
INTERVENTIONAL
2003-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NS 2330
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
40 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Boehringer Ingelheim Study Coordinator
Role: STUDY_CHAIR
Boehringer Ingelheim
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pivotal Reaserch Centers
Peoria, Arizona, United States
Boehringer Ingelheim Investigational Site
Tucson, Arizona, United States
PMDI
Fountain Valley, California, United States
Boehringer Ingelheim Investigational Site
Fresno, California, United States
Boehringer Ingelheim Investigational Site
Irvine, California, United States
Boehringer Ingelheim Investigational Site
Ocenside, California, United States
Boehringer Ingelheim Investigational Site
Oxnard, California, United States
West Los Angeles VA Medical Center
West Los Angeles, California, United States
Boehringer Ingelheim Investigational Site
Danbury, Connecticut, United States
UCONN Health Center
Farmington, Connecticut, United States
60 Temple St
New Haven, Connecticut, United States
Boehringer Ingelheim Investigational Site
Boca Raton, Florida, United States
Boehringer Ingelheim Investigational Site
Bradenton, Florida, United States
University of Florida
Gainsville, Florida, United States
Sunrise Clinical Research
Hollywood, Florida, United States
Department of Neurology
Miami, Florida, United States
Miami Research Associates
Miami, Florida, United States
Boehringer Ingelheim Investigational Site
Ocala, Florida, United States
Renstar Medical Research
Ocala, Florida, United States
Boehringer Ingelheim Investigational Site
Panama City, Florida, United States
CNS Clinical Trials
Saint Piresburg, Florida, United States
Movement Disorder Center
Tampa, Florida, United States
University of Southern Florida
Tampa, Florida, United States
Department of Neurological Sciences
Chicago, Illinois, United States
Boehringer Ingelheim Investigational Site
Fort Wayne, Indiana, United States
Outpatient Clinical Research Facility
Indianapolis, Indiana, United States
Boehringer Ingelheim Investigational Site
Kansas City, Kansas, United States
Boehringer Ingelheim Investigational Site
Shreveport, Louisiana, United States
Boehringer Ingelheim Investigational Site
Scarborough, Maine, United States
Boehringer Ingelheim Investigational Site
Springfield, Massachusetts, United States
Future Care Studies
Springfield, Massachusetts, United States
Boehringer Ingelheim Investigational Site
Traverse City, Michigan, United States
Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota, United States
University of Minesota
Minneapolis, Minnesota, United States
Boehringer Ingelheim Investigational Site
Omaha, Nebraska, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
Global Medical Institutes LLC
Toms River, New Jersey, United States
Upstate Clinical Resaerch LLC
Albany, New York, United States
Boehringer Ingelheim Investigational Site
New York, New York, United States
Boehringer Ingelheim Investigational Site
Wiston-Salem, North Carolina, United States
Ohio State University Medical Center
Columbus, Ohio, United States
Neurology Specialists Inc.
Dayton, Ohio, United States
St. John's Doctor Building
Tulsa, Oklahoma, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
The Methodist Hospital
Houston, Texas, United States
Boehringer Ingelheim Investigational Site
San Antonio, Texas, United States
North Texas Neurology Associates
Wichita Falls, Texas, United States
University of Calgary
Calgary, Alberta, Canada
University of British Columbia
Vancouver, British Columbia, Canada
Davidson Memory Clinic
Moncton, New Brunswick, Canada
Boehringer Ingelheim Investigational Site
Halifax, Nova Scotia, Canada
Centre For Movement Disorders
Markham, Ontario, Canada
Clinical Research Consultant Group
Beaconsfield, Quebec, Canada
Memory and Motor Skills Disorders Clinic
Québec, Quebec, Canada
Boehringer Ingelheim Investigational Site
Saskatoon, Saskatchewan, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1198.100
Identifier Type: -
Identifier Source: org_study_id